Skip to main content
. 2020 Jan 2;156(2):196–200. doi: 10.1001/jamadermatol.2019.4141

Figure 1. Mammalian Target of Rapamycin (mTOR) and Epidermal Growth Factor Receptor (EGFR) Pathway Activation in Patients With Olmsted Syndrome .

Figure 1.

Compared with tissue from the skin of a control patient without Olmsted syndrome (A), tissue from patient 1 (B) and patient 2 (C) that underwent immunostaining showed substantially stronger level of phosphorylated ribosomal protein S6 (RPS6; Ser240/244), a hallmark of mTOR signaling pathway activation, expanded to all layers of the epidermis. Compared with control tissue (D), tissue from patient 1 (E) and patient 2 (F) that underwent immunostaining showed a substantially stronger level of phosphorylated EGFR (Tyr1173), a hallmark of EGFR pathway activation, slightly expanded in the epidermis. DAPI (4′,6-diamidino-2-phenylindole) nuclear counterstain is shown in blue.